Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bausch Health Cos. Inc. stock falls Wednesday, underperforms market

2023-11-22
Shares of Bausch Health Cos. Inc. slipped 0.95% to C$9.39 Wednesday, in what proved to be an otherwise all-around positive trading session for the Canadian...

Piper Sandler Sticks to Its Hold Rating for Bausch Health Companies (BHC)

2023-11-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Bausch Health Cos. Inc. stock falls Tuesday, underperforms market

2023-11-21
Shares of Bausch Health Cos. Inc. slipped 1.86% to C$9.48 Tuesday, in what proved to be an all-around negative trading session for the Canadian market, with...

Is Bausch + Lomb Corporation (NYSE:BLCO) Trading At A 39% Discount?

2023-11-21
Key Insights Using the 2 Stage Free Cash Flow to Equity, Bausch + Lomb fair value estimate is US$25.50 Current share...

Bausch Health Cos. Inc. stock rises Monday, outperforms market

2023-11-20
Shares of Bausch Health Cos. Inc. advanced 2.33% to C$9.66 Monday, in what proved to be an all-around positive trading session for the Canadian market, with...

KBRA Releases Third-Quarter 2023 U.S. Bank Compendium and 2024 Outlook

2023-11-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Bausch Health Cos. Inc. stock rises Friday, outperforms market

2023-11-17
Shares of Bausch Health Cos. Inc. advanced 4.31% to C$9.44 Friday, in what proved to be an all-around positive trading session for the Canadian market, with...

Bausch Health Cos. Inc. stock falls Thursday, underperforms market

2023-11-16
Shares of Bausch Health Cos. Inc. dropped 4.84% to C$9.05 Thursday, in what proved to be an all-around down trading session for the Canadian market, with the...

Encompass Health (EHC) Opens Hospital to Boost Presence in Texas

2023-11-15
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.

Bausch Health Cos. Inc. stock rises Wednesday, outperforms market

2023-11-15
Shares of Bausch Health Cos. Inc. advanced 2.26% to C$9.51 Wednesday, in what proved to be an all-around favorable trading session for the Canadian market,...